carbidopa/levodopa vs cholestyramine
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of carbidopa/levodopa and cholestyramine. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
minor Known Drug Interaction
These include probenecid, cholestyramine, and some antibiotics (e.g., erythromycin, rifampicin, ampicillin and chloramphenicol).
Sinemet
Questran
This medicine contains carbidopa, levodopa, and entacapone. It is used to treat Parkinson's disease.
Cholestyramine is a medicine that helps lower high cholesterol levels in your blood. It works by preventing your body from absorbing cholesterol in the intestines.
This medicine treats Parkinson's disease. It can help when other medicines stop working as well near the end of a dose. It can also replace other medicines containing similar ingredients.
This medicine is used with a diet to lower high cholesterol, especially LDL cholesterol (the "bad" cholesterol). It may also help if you have high triglycerides, but it's not the best choice if high triglycerides are your main problem. Lowering cholesterol helps reduce your risk of heart disease.
Levodopa turns into dopamine in your brain, helping to control movement. Carbidopa helps levodopa get to your brain. Entacapone helps levodopa work longer.
Cholestyramine is a resin that binds to bile acids in your intestines. Bile acids help digest fats, including cholesterol. By binding to bile acids, cholestyramine prevents them from being reabsorbed, so your body uses cholesterol to make more bile acids, which lowers cholesterol levels in your blood.
- • Uncontrolled movements
- • Diarrhea
- • Nausea
- • Belly pain
- • Vomiting
- • Constipation
- Fall 4,293
- Seeing or hearing things that are not there 3,733
- Shaking 3,257
- Uncontrolled movements 2,903
- Death 2,727
- Diarrhoea 1,631
- Fatigue 877
- Nausea 783
- Arthralgia 621
- Headache 543
This medicine can make you fall asleep suddenly, even when you feel awake. Be careful when driving or doing other activities where you need to be alert. Stopping this medicine suddenly can cause serious problems like fever and confusion.
Since cholestyramine can affect how your body absorbs other medicines, take other drugs at least 1 hour before or 4 to 6 hours after taking cholestyramine.
This medicine may harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is not known if this medicine passes into breast milk.
Tell your doctor if you are pregnant or plan to become pregnant. Cholestyramine may affect how you absorb vitamins, so your doctor may recommend supplements. Talk to your doctor about the risks and benefits of taking this medicine while breastfeeding.
Also Compare, Nearby Drugs
Compare cholestyramine with
How to Read This carbidopa/levodopa vs cholestyramine Comparison
carbidopa/levodopa is classified in the Dopamine Precursor Combination drug class, while cholestyramine sits within the Bile Acid Sequestrant class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, carbidopa/levodopa has 16,913 submissions while cholestyramine has 4,455. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known minor interaction flagged in FDA labeling, attributed to cholestyramine can stick to levodopa in your digestive tract and stop it from being absorbed into your bloodstream.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for carbidopa/levodopa or cholestyramine.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.